News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DiaKine Therapeutics, Inc. Release: Combination Drug Therapy May Hold the Key to Reversing Type 1 Diabetes


4/8/2008 8:42:13 AM

SNOWBIRD, Utah--(BUSINESS WIRE)--Seventy percent of mice with type 1 diabetes treated with a combination therapy of Lisofylline (LSF) (DiaKine Therapeutics) and INGAP Peptide (Kinexum Metabolics) went into complete remission and no longer needed insulin, LSF or INGAP Peptide in order to maintain normal blood sugar levels. Additionally, mice treated with this novel combination therapy required less insulin during the treatment regimen than the controls, according to results of a preclinical study presented at the prestigious Keystone Symposia on Beta Cell and Islet Biology.

Read at BioSpace.com

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES